Human intestinal microbiome: Role in health and disease
R Cantón,P De Lucas Ramos,A García-Botella,A García-Lledó,T Hernández-Sampelayo,J Gómez-Pavón,J González Del Castillo,M C Martín-Delgado,F J Martín Sánchez,M Martínez-Sellés,J M Molero García,S Moreno Guillén,F J Rodríguez-Artalejo,E Reigadas,R Del Campo,S Serrano,J Ruiz-Galiana,E Bouza
DOI: https://doi.org/10.37201/req/056.2024
2024-07-09
Abstract:The study of the microbiota and the microbiome, and specifically the intestinal one, has determined great interest due to the possible association of their alterations with numerous diseases. These include entities as diverse as Crohn's disease, autism, diabetes, cancer or situations as prevalent today as obesity. In view of this situation, different recommendations have been performed regarding the use of probiotics, prebiotics, and postbiotics as modulators of the microbiota and the microbiome, seeking both preventive and therapeutic effects, and faecal material transfer (FMT) is proposed as an alternative. The latter has emerged as the only proven beneficial intervention on the intestinal microbiome, specifically in the treatment of recurrent colitis associated with Clostridioides difficile (R-CDI). In the rest of the entities, the lowering of laboratory costs has favored the study of the microbiome, which is resolved by delivering reports with catalogs of microorganisms, metabolites or supposed biomarkers without consensus on their composition associated with healthy or diseased microbiota and the disease. There is still insufficient evidence in any disease for interventions on the microbiome beyond FMT and R-CDI. Multi- and multi-disciplinary work with extensive research and the application of artificial intelligence in this field may shed light on the questions raised currently. Ethical issues must also be resolved in light of possible interventions within the umbrella of personalized medicine.